

In the Specification:

Please amend the specification as indicated below. A "Version With Marking to Show Changes Made to the Specification and the Abstract of the Disclosure" is presented in Appendix A.

Changed for claim One the first page, please replace the title with the following:
METHODS FOR INHIBITING THE INTERACTION OF B7-2 WITH ITS NATURAL
LIGAND

On the first page, please replace the paragraph under the heading "Related Applications", with the following paragraph:

DI This application is a continuation application of U.S. Serial No. 08/479,744, filed on June 5, 1995, now U.S. Patent 6,084,067, which is a continuation-in-part of U.S. Serial No. 08/280,757, entitled "Novel CTLA4/CD28 Ligands and Uses Therefor" filed July 26, 1994, now U.S. Patent No. 6,130,316, which is a continuation-in-part of U.S. Serial No. 08/109,393, entitled "Novel CTLA4/CD28 Ligands and Uses Therefor" filed August 19, 1993, pending, which is a continuation-in-part of U.S. Serial No. 08/101,624, also entitled "Novel CTLA4/CD28 Ligands and Uses Therefor", filed July 26, 1993, now U.S. Patent No. 5,942,607. U.S. Serial No. 08/479,744, now U.S. Patent No. 6,084,067, is also a continuation-in-part of U.S. Serial No. 08/147,773, entitled "Tumor Cells Modified To Express B7-2 And B7-3 With Increased Immunogenicity And Uses Therefor" filed November 3, 1993, now abandoned. The contents of each of these applications is incorporated herein by reference.